Genentech's Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis

Genentech announced 96-week data from the Phase II FENopta open-label extension study showing that patients with relapsing multiple sclerosis (RMS) treated with fenebrutinib maintained no disability progression and low disease activity for up to two years, with an annualized relapse rate of 0.06 and no new active brain lesions detected. The safety profile remained consistent with previous data, and Phase III trial results for fenebrutinib in RMS and primary progressive multiple sclerosis are expected by the end of 2025; fenebrutinib is the only reversible BTK inhibitor in Phase III trials for MS.

Analysis

Genentech, a Roche Group member, reported highly encouraging 96-week data from its Phase II FENopta open-label extension study for fenebrutinib in relapsing multiple sclerosis (RMS). Patients treated with the investigational Bruton’s tyrosine kinase (BTK) inhibitor maintained no disability progression and experienced low disease activity for nearly two years, evidenced by an annualized relapse rate (ARR) of 0.06. MRI scans confirmed suppressed disease activity, with zero new T1 gadolinium-enhancing lesions detected and a significant reduction in new or enlarging T2 lesions (from 6.72 to 0.34 by 96 weeks) in patients switching from placebo. The safety profile remained consistent with previous findings, with the most common adverse events (≥5%) being COVID-19 (10%), urinary tract infection (10%), pharyngitis (6%), and respiratory tract infection (5%), and serious adverse events occurring in 2% of patients. Fenebrutinib is distinguished as a potent, highly selective (130 times more selective for BTK vs. other kinases), and the only reversible BTK inhibitor currently in Phase III trials for multiple sclerosis; its dual inhibition of B-cell and microglia activation may address both disease activity and progression. The first data readouts from the pivotal Phase III studies (FENhance 1 & 2 for RMS and FENtrepid for PPMS) are anticipated by the end of 2025, which will be crucial in characterizing its effects across the MS spectrum. The strongly positive sentiment surrounding this update reflects optimism about fenebrutinib's potential to address unmet needs in MS treatment, particularly disability progression.

Key Decisions for Investors

• Investors should view the positive 96-week Phase II data for fenebrutinib as a significant positive development for Roche's multiple sclerosis pipeline, potentially strengthening its competitive position in the neuroscience market.
• The upcoming Phase III trial results, expected by the end of 2025, represent a key catalyst for Roche (RO, ROG, RHHBY) and should be closely monitored for confirmation of fenebrutinib's efficacy and safety across different MS forms.
• Consider the potential market impact of fenebrutinib, given its differentiated profile as a highly selective, oral, reversible BTK inhibitor, particularly if Phase III results successfully demonstrate a meaningful impact on disability progression in MS.